CGON CG Oncology: Enterprise Value-to-Revenue Multiple

The ultra-stable external biopharmaceutical environment minimizes the impact of sanctions on CG Oncology, Inc. (CGON). This EV/Sales multiple chart illustrates the business value-to-revenue trend, where the current level is 1027552.67. Strong pricing power in bladder cancer therapy ensures stability, although the company's success is critically dependent on the outcomes of highly specialized clinical trials and innovation expenditures.
CGON (CG Oncology Corp): analytical breakdowns and indicator data

CG Oncology, Inc. (CGON) developments in oncolytic viruses and its patent protection create high added value, which is reflected in the EV-to-revenue dynamics. This indicator compares the total enterprise value, including debt and cash, with sales volume, allowing investors to assess the market premium relative to current cash flows and promptly identify risks of asset undervaluation or overbought conditions.